Condition: Focal Segmental Glomerulosclerosis · Minimal Change Disease · Immunoglobulin A Nephropathy · Sponsor: Travere Therapeutics, Inc.
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
This description comes directly from the study's public registry record.
Travere Call Center · 1-877-659-5518 · medinfo@travere.com
Always discuss trial participation with your own doctor first.
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Nemours Children's Hospital | Wilmington, Delaware, United States | Recruiting |
| University of Miami, Leonard M. Miller School of Medicine | Miami, Florida, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| University of Iowa, Stead Family Children's Hospital | Iowa City, Iowa, United States | Withdrawn |
| Floating Hospital for Children at Tufts Medical Center | Boston, Massachusetts, United States | Withdrawn |
| C.S. Mott Children's Hospital | Ann Arbor, Michigan, United States | Recruiting |
| University of Minnesota, Masonic Children's Hospital | Minneapolis, Minnesota, United States | Recruiting |
| Children's Mercy Hospitals and Clinics | Kansas City, Missouri, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Jersey Shore University Medical Center | Neptune City, New Jersey, United States | Recruiting |
| Cohen Children's Medical Center | New Hyde Park, New York, United States | Recruiting |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05003986